Our results indicate that PAMAM-drug-trastuzumab conjugates have increased toxicity toward HER-2-positive human breast cancer cells compared with the free drug or the PAMAM-trastuzumab conjugate. The gene discussed is ERBB2; the disease is breast carcinoma.